Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity

Open Interest and Volume Dynamics

On 9 February 2026, Zydus Lifesciences (symbol: ZYDUSLIFE) recorded an open interest (OI) of 19,970 contracts in its derivatives, marking a robust increase of 3,229 contracts or 19.29% compared to the previous OI of 16,741. This surge in OI was accompanied by a total volume of 28,254 contracts, indicating strong participation in both futures and options segments.

The futures segment alone accounted for a value of approximately ₹28,078.44 lakhs, while the options segment's notional value was substantially higher at ₹20,978.28 crores, culminating in a combined derivatives turnover of ₹31,259.38 lakhs. Such elevated volumes and open interest levels suggest that market participants are actively repositioning, possibly anticipating significant price movements in the near term.

Price Performance and Technical Context

On the same day, Zydus Lifesciences’ stock price touched an intraday high of ₹933.35, gaining 5.09% from the previous close. The stock outperformed its Pharmaceuticals & Biotechnology sector by 2.43% and the Sensex by 3.42%, with a one-day return of 4.04% compared to the sector’s 1.49% and Sensex’s 0.62%. This rebound followed two consecutive days of decline, signalling a potential trend reversal.

Technically, the stock is trading above its 5-day, 20-day, and 50-day moving averages but remains below the 100-day and 200-day averages. This positioning indicates short-term bullish momentum amid longer-term resistance levels. However, delivery volumes have declined by 16.22% against the five-day average, suggesting falling investor participation in the cash segment despite the price rally.

Market Positioning and Sentiment

The sharp increase in open interest alongside rising prices typically points to fresh long positions being built, reflecting bullish sentiment. However, the mixed signals from delivery volumes and the stock’s relative position to longer-term moving averages imply caution. Traders may be speculating on a short-term bounce while remaining wary of broader sectoral or macroeconomic headwinds.

Moreover, the MarketsMOJO Mojo Score for Zydus Lifesciences stands at 43.0, with a recent downgrade from Hold to Sell on 1 December 2025. The Market Cap Grade is 2, categorising it as a mid-cap stock with moderate liquidity and market presence. This downgrade reflects concerns over fundamentals or valuation, which may temper enthusiasm despite the recent price gains and derivatives activity.

Implications of Derivatives Activity on Directional Bets

The surge in open interest and volume in Zydus Lifesciences’ derivatives suggests that traders are actively placing directional bets. The increase in futures open interest, combined with a strong options notional value, indicates that both outright directional plays and hedging strategies are in motion.

Given the stock’s recent price rebound and outperformance, it is plausible that a significant portion of the new open interest represents fresh long positions, anticipating further upside. However, the relatively high options value also points to increased activity in put options, which may be used either for hedging or speculative bearish bets, reflecting some uncertainty.

Investors should note that the weighted average price of traded volumes is closer to the day’s low, which may imply that while the stock touched higher levels intraday, the bulk of trading occurred nearer to lower price points. This could signal profit-taking or cautious accumulation rather than aggressive buying at elevated prices.

Fundamental and Sectoral Context

Zydus Lifesciences operates in the Pharmaceuticals & Biotechnology sector, a space characterised by regulatory complexities and innovation-driven growth. The company’s market capitalisation stands at ₹89,203 crores, placing it firmly in the mid-cap category. Despite the recent downgrade to a Sell rating by MarketsMOJO, the stock’s liquidity remains adequate, with a trade size capacity of approximately ₹1.08 crore based on 2% of the five-day average traded value.

Sectoral performance has been modest, with the Pharmaceuticals & Biotechnology index returning 1.49% on the day, underscoring Zydus Lifesciences’ relative strength. However, investors should weigh this against the company’s fundamental challenges and the broader market environment, which may limit sustained upside.

Investor Takeaway and Outlook

The recent spike in open interest and volume in Zydus Lifesciences’ derivatives market highlights a phase of active repositioning by traders, with a tilt towards bullish bets amid short-term price recovery. However, the downgrade to a Sell rating and the stock’s technical resistance at longer-term moving averages counsel prudence.

Investors should monitor the evolution of open interest in conjunction with price action and delivery volumes to gauge the sustainability of the current momentum. The mixed signals suggest that while short-term gains are possible, underlying fundamental concerns and sectoral headwinds may cap upside potential.

For those considering exposure, a balanced approach incorporating risk management strategies is advisable, especially given the stock’s mid-cap status and moderate liquidity. Watching for confirmation of trend continuation or reversal in the coming sessions will be critical to making informed decisions.

Summary of Key Metrics:

• Open Interest: 19,970 contracts (+19.29%)
• Volume: 28,254 contracts
• Futures Value: ₹28,078.44 lakhs
• Options Notional Value: ₹20,978.28 crores
• Stock Price Intraday High: ₹933.35 (+5.09%)
• Mojo Score: 43.0 (Sell, downgraded from Hold on 01 Dec 2025)
• Market Cap: ₹89,203 crores (Mid Cap)
• Sector Outperformance: +2.43% vs Pharmaceuticals & Biotechnology

In conclusion, Zydus Lifesciences is currently at a crossroads where derivatives market activity signals increased interest and potential directional bets, but fundamental and technical factors urge caution. Investors should stay vigilant and consider the broader market context before committing to fresh positions.

Unlock special upgrade rates for a limited period. Start Saving Now →